- 2009.07.07
- Phase 2 for the clinical study of CBP501, an anticancer drug for non-small-cell lung carcinoma, has begun
(60.1KB) - 2009.04.03
- To increase the efficiency of drug screening methods, NEC's "ChemMiner(TM)" technology was introduced to the screen compounds in candidate pharmaceuticals
- 2009.10.16
- Phase 2 for the clinical study of CBP501, an anticancer drug for malignant pleural mesothelioma, has begun (51KB)
- 2008.06.01
- Report of the Phase 1 clinical study of CBP501 at ASCO2008
- 2008.05.01
- Phase 2 clinical study of the combined usage of CBP501, Pemetrexed and Cisplatin in patients with Malignant Pleural Mesothelioma initiated in the US
